Lipella Pharmaceuticals Inc. is at a critical juncture, struggling financially and facing significant challenges in the competitive biotech sector as it seeks to deliver on its innovative drug delivery platforms.

Lipella Pharmaceuticals Inc. has been delisted from the Nasdaq Capital Market due to regulatory violations, but the company remains operationally sound and is exploring alternative listing options.